Correspondence 0001213900-24-012726 from OS Therapies Inc (OSTX)
OS Therapies Inc
Date: Feb. 12, 2024 · CIK: 0001795091 · Accession: 0001213900-24-012726
AI Filing Summary & Sentiment
File numbers found in text: 333-271034
Show Raw Text
CORRESP
1
filename1.htm
February 12, 2024
VIA EDGAR
Division of Corporation Finance
U.S. Securities & Exchange Commission
100 F Street, NE
Washington, DC 20549
Attention: Office of Life Sciences
Re: OS Therapies Incorporated
Registration Statement on Form S-1
File No. 333-271034
Ladies and Gentlemen:
Pursuant to Rule 461 of
the General Rules and Regulations under the Securities Act of 1933, as amended (the “Act”), the undersigned, for itself and
the other underwriters, hereby join in the request of OS Therapies Incorporated that the effective date of the above-referenced registration
statement be accelerated so as to permit it to become effective at 5:00 p.m., Eastern time, on Wednesday, February 14, 2024, or as soon
thereafter as practicable.
Pursuant to 460 under the
Act, we wish to advise you that the underwriters have distributed as many copies of the preliminary prospectus dated January 24, 2024
to underwriters, dealers, institutions and others as appears to be reasonable to secure adequate distribution of such preliminary prospectus.
The undersigned advises
that it has complied and will continue to comply with the requirements of Rule 15c2-8 under the Securities Exchange Act of 1934, as amended.
Very truly yours,
Boustead Securities, LLC
By:
/s/ Keith Moore
Name:
Keith Moore
Title:
Chief Executive Officer
As representative of the underwriters